TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20522733

Group type: COMPARATOR
Intervention: High-dose EPO (30,000 IU/day for 3 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-dose EPO (5,000 IU/week for 3 months)
Number of subjects: 15
Study: 18972289

Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD PM (1 inhalation)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: MF‐DPI 200 microg BID
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: MF‐DPI 200 microg QD PM
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: MF‐DPI 400 microg QD PM (2 inhalations of 200 microg)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study: 15906422

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (single oral dose)
Number of subjects: 24
Study: 12716810

Group type: EXPERIMENTAL
Intervention: Glargine at dinnertime
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Glargine at bedtime
Number of subjects: 51

Group type: COMPARATOR
Intervention: NPH four times/day
Number of subjects: 51
Study: 10380726

Group type: EXPERIMENTAL
Intervention: Supervised outpatient group training programme (n = 50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standardized recommendations of walking (Control group, n = 51)
Number of subjects: 101
Study: 8970345

Group type: EXPERIMENTAL
Intervention: 750 micrograms
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 75 micrograms
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 7.5 micrograms
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 1944944

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31511031

Group type: EXPERIMENTAL
Intervention: Eutropin (0.24 mg/kg/week, 6 times/week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparator (Genotropin, 0.24 mg/kg/week, 6 times/week)
Number of subjects: 34
Study: 28824042

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ipragliflozin 50 mg
Number of subjects: 30
Study: 26124793

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia at L5, S1 interspace
Number of subjects: 32

Group type: COMPARATOR
Intervention: Spinal anaesthesia at L3, 4 interspace (Control)
Number of subjects: 32
Study: 24100777

Group type: EXPERIMENTAL
Intervention: Web-based program supplemented with mobile phone messages (SMS)
Number of subjects: 3855
Study: 21859972

Group type: EXPERIMENTAL
Intervention: Acetylcysteine 1200 mg
Number of subjects: 2308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2308
Study: 19760932

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole) for 2 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17951228

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQL) measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials
Number of subjects: 0
Study: 15220014

Group type: EXPERIMENTAL
Intervention: Tigecycline 25 mg IV q12h for 7 to 14 days
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tigecycline 50 mg IV q12h for 7 to 14 days
Number of subjects: 160
Study: 11527456

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 25
Study: 9692587

Group type: EXPERIMENTAL
Intervention: bupivacaine 1.5 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine 1.5 mg/kg with 1 in 200000 adrenaline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bupivacaine 3 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: saline
Number of subjects: 100
Study: 7832183

Group type: EXPERIMENTAL
Intervention: Node-link mapping counseling
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group counseling with mapping
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 108
Study: 2971321

Group type: EXPERIMENTAL
Intervention: Thymoxamine (0.1%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30386984

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 446
Study: 28806225

Group type: EXPERIMENTAL
Intervention: Locked procedure pack
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 20
Study: 25561577

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo intervention (PBO)
Number of subjects: 11
Study: 23428340

Group type: EXPERIMENTAL
Intervention: Iterative reconstruction (iDose4) with 80 kVp
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard dose filtered back projection (FBP) with 120 kVp
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard dose filtered back projection (FBP) with 80 kVp
Number of subjects: 80
Study: 20233843

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Active Recovery (ACT)
Number of subjects: 10
Study: 19772452

Group type: EXPERIMENTAL
Intervention: 6 U‐eq capsule (2.6 mg of insulin)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 10 U‐eq capsule (3.9 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 6 U‐eq plus two 2 U‐eq capsules (4.4 mg total)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: two 10 U‐eq capsules (7.8 mg total)
Number of subjects: 59
Study: 17028486

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15471390

Group type: EXPERIMENTAL
Intervention: Long-term morphine-clofelin epidural analgesia and nitroglycerin infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional intravenous morphine
Number of subjects: 90
Study: 11504259

Group type: EXPERIMENTAL
Intervention: Calcium sulfate pellets plus decompression bone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autologous posterior iliac crest bone
Number of subjects: 40
Study: 9257203

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.7 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg/kg
Number of subjects: 45
Study: 8491065

Group type: EXPERIMENTAL
Intervention: Felbamate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3320932

Group type: EXPERIMENTAL
Intervention: Needle wiped with sterile gauze before injection (Group 2)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Same needle used to draw up and inject (Group 3)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Needle changed before injection (Group 1)
Number of subjects: 200
Study: 31180480

Group type: EXPERIMENTAL
Intervention: Oral pregabalin during the perioperative period
Number of subjects: 6

Group type: COMPARATOR
Intervention: Routine analgesia (Control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 6
Study: 28716168

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house-dust mite extract
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26076938

Group type: EXPERIMENTAL
Intervention: Colchicine, 1 mg daily (n=98)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo (n=99)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 23786367

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - victim only
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - perpetrator only
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) - reciprocal violence
Number of subjects: 1044

Group type: COMPARATOR
Intervention: No intimate partner violence (IPV)
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Any type of IPV
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Reciprocal violence
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Victims of IPV
Number of subjects: 1044
Study: 21768314

Group type: EXPERIMENTAL
Intervention: 2 full doses (0.5 mL) of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 252

Group type: COMPARATOR
Intervention: 2 half doses (0.25 mL) of trivalent inactivated influenza vaccine (TIV)
Number of subjects: 252
Study: 19649267

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 3547

Group type: COMPARATOR
Intervention: Comparator drugs (MAS3, artemether-lumefantrine, amodiaquine+sulfadoxine-pyrimethamine, artesunate+amodiaquine)
Number of subjects: 3547
Study: 18029950

Group type: EXPERIMENTAL
Intervention: Intrathecal drug delivery systems (IDDSs)
Number of subjects: 0
Study: 15724519

Group type: EXPERIMENTAL
Intervention: Monaurally fitted with a linear, programmable hearing aid providing over 20-dB insertion gain at 2000-4000 Hz
Number of subjects: 32
Study: 11834959

Group type: EXPERIMENTAL
Intervention: Condom use with clients
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: HIV prevalence
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Syphilis prevalence
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Gonorrhoea prevalence
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Chlamydia prevalence
Number of subjects: 1330
Study: 9428842

Group type: EXPERIMENTAL
Intervention: Dopamine 2.0 micrograms.kg‐1.min‐1 (Group 1, n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Perfusion pressure > 70 mm Hg during CPB (Group 2, n = 7)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dopamine 2.0 micrograms.kg‐1.min‐1 (Group 1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Perfusion pressure > 70 mm Hg during CPB (Group 2)
Number of subjects: 17
Study: 7647223

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential compression devices (SCD)
Number of subjects: 0
Study: 2729166

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous saccharate (10% Fe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 0
Study: 870369

Group type: EXPERIMENTAL
Intervention: D-penicillamine and a low copper diet
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31283365

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham Yoga (Control)
Number of subjects: 40
Study: 28656801

Group type: EXPERIMENTAL
Intervention: Malingering for the purpose of receiving stimulant medication
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Malingering for the purpose of receiving extra time accommodations
Number of subjects: 167

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 167

Group type: COMPARATOR
Intervention: Individuals with ADHD
Number of subjects: 167
Study: 28143840

Group type: EXPERIMENTAL
Intervention: Complex intervention targeting physicians and pharmacist assistants, including a 2-day training workshop, educational outreach visits at 3, 6, and 9 months, an app for decision aid, and a web-based platform for SMS messages to patients.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 350
Study: 24451696

Group type: EXPERIMENTAL
Intervention: Stretching group (SG, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study: 22544676

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 15 minutes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 21526889

Group type: EXPERIMENTAL
Intervention: LRPT 40 mg co-administered with clopidogrel 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LRPT 40 mg co-administered with aspirin 81 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 81 mg alone
Number of subjects: 0
Study: 17602789

Group type: EXPERIMENTAL
Intervention: Ethanol 40 g/day administered at two main meals for 30 days (beer)
Number of subjects: 40
Study: 16519142

Group type: EXPERIMENTAL
Intervention: Microdeletion detection using multiplex PCR
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no microdeletion)
Number of subjects: 67
Study: 12918862

Group type: EXPERIMENTAL
Intervention: Cervical mobilization (contralateral lateral glide technique)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 20
Study: 10969672

Group type: EXPERIMENTAL
Intervention: Preoperative intraaortic balloon pump therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: High-risk coronary artery bypass graft without preoperative intraaortic balloon pump therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Low-risk coronary artery bypass graft operations
Number of subjects: 112
Study: 9080162

Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated circuits
Number of subjects: 151

Group type: COMPARATOR
Intervention: Uncoated circuits
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study: 7504387

Group type: EXPERIMENTAL
Intervention: 20 ml.kg-1 LMW-HES (Mw 120,000)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 ml.kg-1 HMW-HES (Mw 400,000)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ringer's acetate 2000 ml
Number of subjects: 45
Study: 3531957

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment directed to the leakage site, using spot sizes of 200 mu in diameter, exposure times of 0.2 seconds, and low‐power intensities.
Number of subjects: 0
Study: 29318424

Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg long-acting release
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9 %)
Number of subjects: 34
Study: 26792419

Group type: EXPERIMENTAL
Intervention: Norepinephrine to maintain MAP at pre-anaesthesia levels
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group receiving vasopressor if MAP decreased below 60 mmHg
Number of subjects: 24
Study: 25471989

Group type: EXPERIMENTAL
Intervention: Isolated ankle strengthening
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Functional balance training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Activity-matched control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 23208763

Group type: EXPERIMENTAL
Intervention: Placental growth factor (PlGF) at visit 1
Number of subjects: 772
Study: 21553161

Group type: EXPERIMENTAL
Intervention: Regadenoson (400-μg bolus injection)
Number of subjects: 2015

Group type: COMPARATOR
Intervention: Adenosine (6-minute infusion)
Number of subjects: 2015
Study: 18373605

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study: 16986154

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including feedback, education, alcohol-based hand wash, and visual reminders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 12743984

Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m2 and vinorelbine 20 mg/m2 on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: gemcitabine and vinorelbine
Number of subjects: 30
Study: 10892276

Group type: EXPERIMENTAL
Intervention: Adatocel (methylhydroxypropylcellulose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Amvisc Plus (sodium hyaluronate)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate)
Number of subjects: 150
Study: 8881952

Group type: EXPERIMENTAL
Intervention: Free PSA in patients with localized CaP (median 8.8%)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Free PSA in patients with metastatic CaP (median 7.1%)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Free PSA in patients with BPH (median 19.5%)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Free PSA in patients with urolithiasis (median 18.8%)
Number of subjects: 145
Study: 1356311

Group type: EXPERIMENTAL
Intervention: xamoterol 100 mg two times a day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg two times a day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: verapamil 240 mg once a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: all active treatments
Number of subjects: 21
Study: 2826563

Group type: EXPERIMENTAL
Intervention: Fiber (15 g daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29122620

Group type: EXPERIMENTAL
Intervention: Convective RF thermal therapy with Rezūm System
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control (rigid cystoscopy with simulated active treatment sound effects)
Number of subjects: 197
Study: 28404067

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration with bupivacaine plus patient-controlled analgesia with morphine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine and sufentanil
Number of subjects: 105
Study: 24861192

Group type: EXPERIMENTAL
Intervention: Decubitus position with 10 mg of 0.5% bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sitting position with 10 mg of 0.5% bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Decubitus and Sitting)
Number of subjects: 80
Study: 22574801

Group type: EXPERIMENTAL
Intervention: Competitive Memory Training (COMET)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 77
Study: 20550533

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily for 36 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 18431674

Group type: EXPERIMENTAL
Intervention: Fast dissolving films containing TC-Poloxamer 407
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eugenol containing films
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fast dissolving films containing TC-HPBCD complex
Number of subjects: 0
Study: 16390890

Group type: EXPERIMENTAL
Intervention: DHEA (100-400 mg/day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 145

Group type: COMPARATOR
Intervention: DHEA and Placebo
Number of subjects: 145
Study: 12728743

Group type: EXPERIMENTAL
Intervention: Once-daily administration of quetiapine (400 or 600 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Twice-daily administration of quetiapine (400 or 600 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Once-daily administration of quetiapine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Twice-daily administration of quetiapine
Number of subjects: 21
Study: 9890410

Group type: EXPERIMENTAL
Intervention: Pure oxygen administration for 30 min
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pure oxygen administration for 30 min with right atrial pacing in 12 patients
Number of subjects: 35
Study: 7484891

Group type: EXPERIMENTAL
Intervention: Thrombolysis (Group A)
Number of subjects: 434

Group type: COMPARATOR
Intervention: No thrombolysis (Group B)
Number of subjects: 434
Study: 2076623

Group type: EXPERIMENTAL
Intervention: Naproxen gel (10%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flufenamic acid gel (3%)
Number of subjects: 100
Study: 375088

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 113

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 113
Study: 31359460

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 140
Study: 28885314

Group type: EXPERIMENTAL
Intervention: SADBE
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SADBE (after switching from vehicle)
Number of subjects: 36
Study: 25733777

Group type: EXPERIMENTAL
Intervention: Mediterranean-like dietary counseling
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (2.4 g/d)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 563
Study: 23802816

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 13686

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 13686
Study: 21668387

Group type: EXPERIMENTAL
Intervention: ABG‐I stem
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unique customized femoral stem
Number of subjects: 100
Study: 19192976

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10/160 mg
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg
Number of subjects: 947

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 947
Study: 16723303

Group type: EXPERIMENTAL
Intervention: HT25 (0.025 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: HT50 (0.050 mg/day)
Number of subjects: 66
Study: 15523323

Group type: EXPERIMENTAL
Intervention: High-dose enalapril
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low-dose enalapril
Number of subjects: 74
Study: 11421866

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375